Our science

Metabolic dysregulation and oncology are propagated by complex pathophysiologies requiring innovative approaches based on a deep understanding of metabolic signalling pathways and nuclear receptor transcriptional processes to drive novel approaches against key targets as therapeutic entry points.
Research and innovation at TES Pharma is thus aimed at novel disease modifying approaches using small molecule ligands and on realizing the potential of nuclear receptors as modulators of disease to unlock the potential of bile acid derivatives as therapeutic agents.

Collaboration with world centres of excellence ensures that our projects are pursued with a broad and in-depth understanding of the chemistry and biology necessary to develop novel efficacious disease modifying treatments.

TES Pharma is dedicated enhancing local scientific excellence by promoting the growth and exchange of young researchers from academia to pharmaceutical research.